Monotherapy of an NMDA Enhancer for Schizophrenia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE2

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-01-01

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Previous studies found that some NMDA-enhancing agent was able to augment antioxidant activity and its adjunctive therapy was better than placebo in reducing clinical symptoms and cognitive deficits and revealed favorable safety in patients with chronic schizophrenia. Of note, a substantial portion of schizophrenia patients refuse or cannot tolerate antipsychotics due to poor response or severe side effects. Therefore, this study aims to examine the efficacy and safety of an NMDA enhancer (NMDAE) as a monotherapy for the treatment of schizophrenia.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Combination of NMDA-enhancing and Antioxidant Treatments for Schizophrenia

NCT04959201

Schizophrenia

RECRUITING PHASE2

Early Intervention of Prodromal Schizophrenia Using an NMDA Enhancer

NCT05052853

Prodromal Schizophrenia

RECRUITING PHASE2

NMDA-enhancing Treatment for Cognitive Dysfunction of Schizophrenia

NCT06021197

Schizophrenia

RECRUITING PHASE2

Combination of NMDA-enhancing and Anti-inflammatory Treatments for Schizophrenia

NCT04917302

Schizophrenia

RECRUITING PHASE2

Combination of NMDA-enhancing and Anti-inflammatory Treatments for Ultra-resistant Schizophrenia

NCT05240976

Schizophrenia

RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Several lines of evidence suggest that schizophrenia is associated with accelerated aging and oxidative stress may play a role. Cognitive deficits are core symptoms of accelerated aging in patients with schizophrenia and the most difficult domain to treat. Current antipsychotics have limited, if any, efficacy for cognitive function. Previous studies found that some NMDA-enhancing agent was able to augment antioxidant activity and its adjunctive therapy was better than placebo in reducing not only clinical symptoms but also cognitive deficits and revealed favorable safety in patients with chronic schizophrenia. Of note, a substantial portion of schizophrenia patients refuse or cannot tolerate antipsychotics due to poor response or severe side effects. This study aims to examine the efficacy and safety of NMDAE monotherapy for the treatment of schizophrenia. The investigators enroll patients with schizophrenia who refuse or are unable to tolerate antipsychotics due to poor response or adverse effects into a 6-week randomized, double-blind trial to receive monotherapy of NMDAE or placebo. The investigators biweekly measure clinical performances and side effects. Cognitive functions are assessed at baseline and at endpoint of treatment by a battery of tests. The efficacies of NMDAE and placebo will be compared.

Chi-square (or Fisher's exact test) will be used to compare differences of categorical variables and t-test (or Mann-Whitney test if the distribution is not normal) for continuous variables between treatment groups. Mean changes from baseline in repeated-measure assessments will be assessed using the generalized estimating equation (GEE). All p values for clinical measures will be based on two-tailed tests with a significance level of 0.05.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Schizophrenia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

NMDAE

An NMDA enhancer

Group Type EXPERIMENTAL

NMDAE

Intervention Type DRUG

Use of an NMDA enhancer for the treatment of schizophrenia

Placebo

Group Type PLACEBO_COMPARATOR

Placebo Cap

Intervention Type DRUG

Use of placebo as a comparator

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

NMDAE

Use of an NMDA enhancer for the treatment of schizophrenia

Intervention Type DRUG

Placebo Cap

Use of placebo as a comparator

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Have a DSM-5 (American Psychiatric Association) diagnosis of schizophrenia
* Refuse or are unable to tolerate antipsychotics due to poor response or adverse effects
* PANSS total score ≥ 60
* Free of antipsychotic drugs for at least 1 week
* Agree to participate in the study and provide informed consent

Exclusion Criteria

* Current substance abuse or history of substance dependence in the past 3 months
* History of epilepsy, head trauma, stroke or other serious medical or neurological illness which may interfere with the study
* Use of depot antipsychotic in the past 3 months;
* Clinically significant laboratory screening tests
* Pregnancy or lactation
* Inability to follow protocol

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No